Prolonged treatments with antiresorptive agents and PTH have different effects on bone strength and the degree of mineralization in old estrogen-deficient osteoporotic rats

Journal of Bone and Mineral Research

Volumn 24, Issue 2, 2009, Pages 209-220

  Cheng, Zhiqiang ^a   Yao, Wei ^a   Zimmermann, Elizabeth A ^b   Busse, Cheryl ^a   Ritchie, Robert O ^b   Lane, Nancy E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b No 1760   (United States)

Author keywords

Bone mineral homogeneity; Bone mineralization; Compression and bending strengths; Intravenous bisphosphonates; PTH(1 34)

Indexed keywords

PARATHYROID HORMONE[1-34]; RALOXIFENE; RISEDRONIC ACID; ZOLEDRONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MASS; BONE MINERALIZATION; BONE STRENGTH; BONE TURNOVER; COMPRESSION; CONTROLLED STUDY; CORTICAL BONE; ESTROGEN DEFICIENCY; FEMALE; LUMBAR VERTEBRA; METAPHYSIS; MICRO-COMPUTED TOMOGRAPHY; MORPHOMETRICS; NONHUMAN; OSTEOPENIA; OSTEOPOROSIS; RAT; SINGLE DRUG DOSE; TIBIA; TRABECULAR BONE; VERTEBRA BODY; YOUNG MODULUS;

AGING; ANIMALS; BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; BONE RESORPTION; CALCIFICATION, PHYSIOLOGIC; DISEASE MODELS, ANIMAL; ELASTIC MODULUS; ESTROGENS; FEMALE; LUMBAR VERTEBRAE; OSTEOPOROSIS; OVARIECTOMY; PARATHYROID HORMONE; RATS; RATS, INBRED F344; REPRODUCIBILITY OF RESULTS; TIBIA; TIME FACTORS; X-RAY MICROTOMOGRAPHY;

EID: 58649123545     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.81005     Document Type: Article

References (64)

1. Iacono MV 2007 Osteoporosis: A national public health priority. J Perianesth Nurs 22:175-180.
2. Russell RG, Rogers MJ 1999 Bisphosphonates: From the laboratory to the clinic and back again. Bone 25:97-106.
3. Harrington JT, Ste-Marie LG, Brandi ML, Civitelli R, Fardellone P, Grauer A, Barton I, Boonen S 2004 Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int 74:129-135.
4. Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW Jr, Dequeker J, Favus M 1995 Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 333:1437-1443.
5. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH III, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD 1999 Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282:1344- 1352.
6. Reeve J, Meunier PJ, Parsons JA, Bernat M, Bijvoet OL, Courpron P, Edouard C, Klenerman L, Neer RM, Renier JC, Slovik D, Vismans FJ, Potts JT Jr 1980 Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: A multicentre trial. BMJ 280:1340-1344.
7. Mitlak BH, Burdette-Miller P, Schoenfeld D, Neer RM 1996 Sequential effects of chronic human PTH (1-84) treatment of estrogen-deficiency osteopenia in the rat. J Bone Miner Res 11:430-439.
8. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH 2001 Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434-1441.
9. Burr DB 2005 Does early PTH treatment compromise bone strength? The balance between remodeling, porosity, bone mineral, and bone size Curr Osteoporos Rep 3:19-24.
10. Hirano T, Burr DB, Turner CH, Sato M, Cain RL, Hock JM 1999 Anabolic effects of human biosynthetic parathyroid hormone fragment (1-34), LY333334, on remodeling and mechanical properties of cortical bone in rabbits. J Bone Miner Res 14:536-545.
11. Burr DB, Hirano T, Turner CH, Hotchkiss C, Brommage R, Hock JM 2001 Intermittently administered human parathyroid hormone(1-34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys. J Bone Miner Res 16:157-165.
12. Dempster DW, Cosman F, Kurland ES, Zhou H, Nieves J, Woelfert L, Shane E, Plavetic K, Muller R, Bilezikian J, Lindsay R 2001 Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: A paired biopsy study. J Bone Miner Res 16:1846-1853.
13. Hodsman AB, Kisiel M, Adachi JD, Fraher LJ, Watson PH 2000 Histomorphometric evidence for increased bone turnover without change in cortical thickness or porosity after 2 years of cyclical hPTH(1-34) therapy in women with severe osteoporosis. Bone 27:311-318.
14. Follet H, Boivin G, Rumelhart C, Meunier PJ 2004 The degree of mineralization is a determinant of bone strength: A study on human calcanei. Bone 34:783-789.
15. Borah B, Ritman EL, Dufresne TE, Jorgensen SM, Liu S, Sacha J, Phipps RJ, Turner RT 2005 The effect of risedronate on bone mineralization as measured by micro-computed tomography with synchrotron radiation: Correlation to histomorphometric indices of turnover. Bone 37:1-9.
16. Borah B, Dufresne TE, Ritman EL, Jorgensen SM, Liu S, Chmielewski PA, Phipps RJ, Zhou X, Sibonga JD, Turner RT 2006 Long-term risedronate treatment normalizes mineralization and continues to preserve trabecular architecture: Sequential triple biopsy studies with micro-computed tomography. Bone 39:345-352.
17. Allen MR, Iwata K, Sato M, Burr DB 2006 Raloxifene enhances vertebral mechanical properties independent of bone density. Bone 39:1130-1135.
18. Kinney JH, Pople JA, Marshall GW, Marshall SJ 2001 Collagen orientation and crystallite size in human dentin: A small angle X-ray scattering study. Calcif Tissue Int 69:31-37.
19. Lane NE, Yao W, Balooch M, Nalla RK, Balooch G, Habelitz S, Kinney JH, Bonewald LF 2006 Glucocorticoid-treated mice have localized changes in trabecular bone material properties and osteocyte lacunar size that are not observed in placebo-treated or estrogen-deficient mice. J Bone Miner Res 21:466-476.
20. Yao W, Cheng Z, Koester KJ, Ager JW, Balooch M, Pham A, Chefo S, Busse C, Ritchie RO, Lane NE 2007 The degree of bone mineralization is maintained with single intravenous bisphosphonates in aged estrogen-deficient rats and is a strong predictor of bone strength. Bone 41:804-812.
21. Gasser JA, Green JR, Shen V, Ingold P, Rebmann A, Bhatnagar AS, Evans DB 2006 A single intravenous administration of zoledronic acid prevents the bone loss and mechanical compromise induced by aromatase inhibition in rats. Bone 39:787-795.
22. Ma YL, Bryant HU, Zeng Q, Schmidt A, Jee WS, Sato M 2005 Raloxifene and teriparatide (hPTH 1-34) have complementary effects on the osteopenic skeleton of ovariectomized rats. J Bone Miner Metab 23 (Suppl):62-68.
23. Yao W, Su M, Zhang Q, Tian X, Setterberg RB, Blanton C, Lundy MW, Phipps R, Jee WS 2007 Risedronate did not block the maximal anabolic effect of PTH in aged rats. Bone 41:813-819.
24. Lane NE, Yao W, Kinney JH, Modin G, Balooch M, Wronski TJ 2003 Both hPTH(1-34) and bFGF increase trabecular bone mass in osteopenic rats but they have different effects on trabecular bone architecture. J Bone Miner Res 18:2105-2115.
25. Yao W, Hadi T, Jiang Y, Lotz J, Wronski TJ, Lane NE 2005 Basic fibroblast growth factor improves trabecular bone connectivity and bone strength in the lumbar vertebral body of osteopenic rats. Osteoporos Int 16:1939-1947.
26. Kinney JH, Haupt DL, Balooch M, Ladd AJ, Ryaby JT, Lane NE 2000 Three-dimensional morphometry of the L6 vertebra in the ovariectomized rat model of osteoporosis: Biomechanical implications. J Bone Miner Res 15:1981-1991.
27. Lane NE, Kumer J, Yao W, Breunig T, Wronski T, Modin G, Kinney JH 2003 Basic fibroblast growth factor forms new trabeculae that physically connect with pre-existing trabeculae, and this new bone is maintained with an anti-resorptive agent and enhanced with an anabolic agent in an osteopenic rat model. Osteoporos Int 14:374-382.
28. Balooch G, Marshall GW, Marshall SJ, Warren OL, Asif SA, Balooch M 2004 Evaluation of a new modulus mapping technique to investigate microstructural features of human teeth. J Biomech 37:1223-1232.
29. Boivin GY, Chavassieux PM, Santora AC, Yates J, Meunier PJ 2000 Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 27:687-694.
30. Jee WS, Mori S, Li XJ, Chan S 1990 Prostaglandin E2 enhances cortical bone mass and activates intracortical bone remodeling in intact and ovariectomized female rats. Bone 11:253-266.
31. Yao W, Balooch G, Balooch M, Jiang Y, Nalla RK, Kinney J, Wronski TJ, Lane NE 2006 Sequential treatment of ovariectomized mice with bFGF and risedronate restored trabecular bone microarchitecture and mineralization. Bone 39:460-469.
32. Yao W, Jee WS, Chen J, Liu H, Tarn CS, Cui L, Zhou H, Setterberg RB, Frost HM 2000 Making rats rise to erect bipedal stance for feeding partially prevented orchidectomy-induced bone loss and added bone to intact rats. J Bone Miner Res 15:1158-1168.
33. Bentolila V, Boyce TM, Fyhrie DP, Drumb R, Skerry TM, Schaffler MB 1998 Intracortical remodeling in adult rat long bones after fatigue loading. Bone 23:275-281.
34. Balooch G, Yao W, Ager JW, Balooch M, Nalla RK, Porter AE, Ritchie RO, Lane NE 2007 The aminobisphosphonate risedronate preserves localized mineral and material properties of bone in the presence of glucocorticoids. Arthritis Rheum 56:3726-3737.
35. Wasnich RD, Miller PD 2000 Antifracture efficacy of anti-resorptive agents are related to changes in bone density. J Clin Endocrinol Metab 85:231-236.
36. Chesnut CH III, Rosen CJ 2001 Reconsidering the effects of antiresorptive therapies in reducing osteoporotic fracture. J Bone Miner Res 16:2163-2172.
37. Cummings SR, Karpf DB, Harris F, Genant HK, Ensrud K, LaCroix AZ, Black DM 2002 Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 112:281-289.
38. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE 1996 Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535-1541.
39. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR 1999 Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282:637-645.
40. Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R 2000 Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11:83-91.
41. Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC, Nevitt MC, Suryawanshi S, Cummings SR 2000 Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 85:4118-4124.
42. Heaney RP, Zizic TM, Fogelman I, Olszynski WP, Geusens P, Kasibhatla C, Alsayed N, Isaia G, Davie MW, Chesnut CH III 2002 Risedronate reduces the risk of first vertebral fracture in osteoporotic women. Osteoporos Int 13:501-505.
43. Delmas PD, Ensrud KE, Adachi JD, Harper KD, Sarkar S, Gennari C, Reginster JY, Pols HA, Recker RR, Harris ST, Wu W, Genant HK, Black DM, Eastell R 2002 Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: Four-year results from a randomized clinical trial. J Clin Endocrinol Metab 87:3609-3617.
44. Sarkar S, Mitlak BH, Wong M, Stock JL, Black DM, Harper KD 2002 Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res 17:1-10.
45. Zoehrer R, Roschger P, Paschalis EP, Hofstaetter JG, Durchschlag E, Fratzl P, Phipps R, Klaushofer K 2006 Effects of 3- and 5-year treatment with risedronate on bone mineralization density distribution in triple biopsies of the iliac crest in postmenopausal women. J Bone Miner Res 21:1106-1112.
46. Durchschlag E, Paschalis EP, Zoehrer R, Roschger P, Fratzl P, Recker R, Phipps R, Klaushofer K 2006 Bone material properties in trabecular bone from human iliac crest biopsies after 3- and 5-year treatment with risedronate. J Bone Miner Res 21:1581-1590.
47. Roschger P, Rinnerthaler S, Yates J, Rodan GA, Fratzl P, Klaushofer K 2001 Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women. Bone 29:185-191.
48. Bauss F, Dempster DW, 2007 Effects of ibandronate on bone quality: Preclinical studies. Bone 40:265-273.
49. Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, Satterfield S, Wallace RB, Bauer DC, Palermo L, Wehren LE, Lombardi A, Santora AC, Cummings SR 2006 Effects of continuing or stopping alendronate after 5 years of treatment; The Fracture Intervention Trial Long-term Extension (FLEX): A randomized trial. JAMA 296:2927-2938.
50. Boskey AL, DiCarlo E, Paschalis E, West P, Mendelsohn R 2005 Comparison of mineral quality and quantity in iliac crest biopsies from high- and low-turnover osteoporosis: An FT-IR microspectroscopic investigation. Osteoporos Int 16:2031-2038.
51. Paschalis EP, Glass EV, Donley DW, Eriksen EF 2005 Bone mineral and collagen quality in iliac crest biopsies of patients given teriparatide; New results from the fracture prevention trial. J Clin Endocrinol Metab 90:4644-4649.
52. Zioupos P, Currey JD, Hamer AJ 1999 The role of collagen in the declining mechanical properties of aging human cortical bone. J Biomed Mater Res 45:108-116.
53. Wergedal J, Stauffer M, Baylink D, Rich C 1973 Inhibition of bone matrix formation, mineralization, and resorption in thyroparathyroidectomized rats. J Clin Invest 52:1052-1058.
54. Midura RJ, Evanko SP, Hascall VC 1994 Parathyroid hormone stimulates hyaluronan synthesis in an osteoblast-like cell line. J Biol Chem 269:13200-13206.
55. Midura RJ, Su X, Morcuende JA, Tammi M, Tammi R 2003 Parathyroid hormone rapidly stimulates hyaluronan synthesis by periosteal osteoblasts in the tibial diaphysis of the growing rat. J Biol Chem 278:51462-51468.
56. Bonewald LF 2007 Osteocytes as dynamic, multifunctional cells. Ann NY Acad Sci 1116:281-290.
57. Rath Bonivtch A, Bonewald LF, Nicolella DP 2007 Tissue strain amplification at the osteocyte lacuna: A microstructural finite element analysis. J Biomech 40:2199-2206.
58. Plotkin LI, Aguirre JI, Kousteni S, Manolagas SC, Bellido T 2005 Bisphosphonates and estrogens inhibit osteocyte apoptosis via distinct molecular mechanisms downstream of extracellular signal-regulated kinase activation. J Biol Chem 280:7317-7325.
59. Tomkinson A, Gevers EF, Wit JM, Reeve J, Noble BS 1998 The role of estrogen in the control of rat osteocyte apoptosis. J Bone Miner Res 13:1243-1250.
60. Mann V, Huber C, Kogianni G, Collins F, Noble B 2007 The antioxidant effect of estrogen and Selective Estrogen Receptor Modulators in the inhibition of osteocyte apoptosis in vitro. Bone 40:674-684.
61. Jilka RL, Weinstein RS, Parfitt AM, Manolagas SC 2007 Quantifying osteoblast and osteocyte apoptosis; Challenges and rewards. J Bone Miner Res 22:1492-1501.
62. Misof BM, Roschger P, Cosman F, Kurland ES, Tesch W, Messmer P, Dempster DW, Nieves J, Shane E, Fratzl P, Klaushofer K, Bilezikian J, Lindsay R 2003 Effects of intermittent parathyroid hormone administration on bone mineralization density in iliac crest biopsies from patients with osteoporosis: A paired study before and after treatment. J Clin Endocrinol Metab 88:1150-1156.
63. Tai K, Dao M, Suresh S, Palazoglu A, Ortiz C 2007 Nanoscale heterogeneity promotes energy dissipation in bone. Nat Mater 6:454-462.
64. Iida-Klein A, Lu SS, Cosman F, Lindsay R, Dempster DW 2007 Effects of cyclic vs. daily treatment with human parathyroid hormone (1-34) on murine bone structure and cellular activity. Bone 40:391-398.